Filtered By:
Specialty: Drugs & Pharmacology
Therapy: Statin Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1155 results found since Jan 2013.
Molecular Complex of HSIM-loaded Polymeric Nanoparticles: Potential Carriers in Osteoporosis
CONCLUSION: Bone-targeting nanoparticles incorporating functionalized simvastatin can target bone. Thus, in order to distribute simvastatin subcutaneously for the treatment of osteoporosis, the developed nanoparticles may act as a promising approach.PMID:37718521 | DOI:10.2174/1389450124666230915092910
Source: Current Drug Targets - September 18, 2023 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Amarjot Kaur Grewal Samrat Chauhan Chander Parkash Dora Thakur Gurjeet Singh Source Type: research
Emerging therapies in dyslipidaemias
Vascul Pharmacol. 2023 Sep 14:107229. doi: 10.1016/j.vph.2023.107229. Online ahead of print.ABSTRACTSeveral observations have shown that elevated levels of low-density lipoprotein cholesterol (LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for reducing cardiovascular risk, with a continuous linear correlation between LDL-C reduction and cardiovascular benefit. Based on these observations, current guidelines have further lowered LDL-C goals and call for the use of more effective therapeutic interventions. In addition to statins, ezetimibe and the monoclonal antibodies targeting PCSK9, several...
Source: Vascular Pharmacology - September 16, 2023 Category: Drugs & Pharmacology Authors: Alberico L Catapano Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Statin as repurposed drug in Ovarian Cancer: A comprehensive review
Curr Pharm Des. 2023 Sep 13. doi: 10.2174/1381612829666230913113808. Online ahead of print.ABSTRACTWith a prevalence rate of 6.6 per 100,000 women, ovarian cancer is the third most lethal gynecological tumor in the world. Several factors like family history, nulliparity, late menopause, genetic mutation, and an unhealthy lifestyle contribute to increasing the risk of ovarian cancer development. Novel research studies suggest that ovarian cancer may be caused by changes in the lipid metabolic profile that trigger inflammatory responses. Moreover, ovarian cancer patients will eventually experience chemoresistance. Statin, a ...
Source: Current Pharmaceutical Design - September 15, 2023 Category: Drugs & Pharmacology Authors: Asmara Ahmad Sadia Javed Shumaila Kiran Source Type: research
The influence of atorvastatin, amlodipine and ethoxidol on ubiquinol and ubiquinone endogenous plasma concentrations in patients with chronic heart failure
CONCLUSION: Amlodipine is able to neutralize the negative effect of atorvastin on the redox balance of CoQ10 in patients with CHF. An additional prescription of the antioxidant ethoxidol to standard therapy for patients with CHF was substantiated. Determination of the redox state of CoQ10 in plasma can be used to diagnose and assess the degree of oxidative stress in patients with cardiovascular diseases, as well as to assess the efficacy and safety of ongoing pharmacotherapy.PMID:37711113 | DOI:10.2174/1389200224666230913133201
Source: Current Drug Metabolism - September 15, 2023 Category: Drugs & Pharmacology Authors: Vladlena I Zozina Svetlana N Kondratenko Evgenia V Shikh Liudmila M Krasnykh Evgeny S Melnikov Vladimir G Kukes Source Type: research
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
Acta Pharm. 2023 Sep 14;73(3):363-384. doi: 10.2478/acph-2023-0034. Print 2023 Sep 1.ABSTRACTThe advancements in proteomics have provided a better understanding of the functionality of apolipoproteins and lipoprotein-associated proteins, with the HDL lipoprotein fraction being the most studied. The focus of this study was to evaluate the HDL proteome in dyslipidemic subjects without an established cardiovascular disease, as well as to test whether rosuvastatin treatment alters the HDL proteome. Patients with primary hypercholesterolemia or mixed dyslipidemia were assigned to 20 mg/day rosuvastatin and blood samples were dr...
Source: Acta Pharmaceutica - September 14, 2023 Category: Drugs & Pharmacology Authors: Ana Vavlukis Kristina Mladenovska Katarina Davalieva Marija Vavlukis Aleksandar Dimovski Source Type: research
